回复@走向自由: 你说那个是一个特定的专利（U.S. Patent No. 10,808,039）的侵权，seagen之前已经赢了，拿了enhertu之前销售额的赔偿，有四千多万，以后估计也能抽成。这个仲裁针之前2008年一个合作导致的争议，seagen认为第一三共的连接子和其他一些专利归属权应该自动归$Seagen(SGEN)$ ，这覆盖更大范围。
Separately, Seagen is engaged in an arbitration it brought against Daiichi Sankyo over ownership of certain technology used by Daiichi Sankyo in trastuzumab deruxtecan and several other drug candidates. In the arbitration, which remains ongoing, Seagen contends that the linker and other ADC technology used in these compounds are improvements to Seagen’s pioneering ADC technology, the ownership of which is automatically assigned to Seagen under the 2008 collaboration agreement between Daiichi Sankyo and Seagen.//@走向自由:回复@JZee:请教一下，是这个的后续么:第一三共二审败诉Seagen，重磅ADC DS-8201被判侵权